Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) said that the management has appointed Lorianne Masuoka, MD, as new Chief Medical Officer of the company, effective March 2, 2015. As of now, the position was held by interim Chief Medical Officer, Lou Vaickus, MD, who is President and Founder of a reputed Life Sciences Consulting Firm known as akta Pharmaceutical Development LLC.
Before Dr. Masuoka commenced its journey with Invivo, she has served on various senior profiles. She has been on the post of Chief Medical Officer at Cubist Pharmaceuticals. Also, she was Senior VP of the company during the same time. As a senior member of executive management team, Dr. Masuoka managed more than 150 personnel employed in the division of clinical research, data management, clinical operations, drug safety, and biostatistics. The experiences of being CMO at Cubist will a great asset during her tenure with Invivo.
Prior to joining Cubist, Dr. Masuoka has served in various senior roles at Nektar Therapeutics. She served as Chief Medical Officer and Senior VP with Nektar from August 2008 until August 2011. She was associated with FivePrime Therapeutics from July 2003 to August 2008 as VP, Clinical Development. She headed the Department of Clinical Development, Oncology at Chiron. Dr. Masuoka is a professional graduate with a medical degree from the “University of California”. She pursued her residency in neurology from the same university.
Asset for company
Mark Perrin, the CEO of Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) said that the management of Invivo is delighted to have Dr. Masuoka to have on board. She will be a strong asset to the company especially during the transition period when the company is working on the expedited timeline of its pilot trial to design pivotal trial. The experience in the relevant field makes her an invaluable asset as Invivo moves forward with its clinical programs.